Cargando…

Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses

BACKGROUND: Among patients with nondialysis-dependent chronic kidney disease (NDD-CKD) and iron-deficiency anemia (IDA), ferric citrate increases hemoglobin and iron parameters and reduces serum phosphate and fibroblast growth factor 23 (FGF23), a key phosphate-regulating hormone. We conducted post...

Descripción completa

Detalles Bibliográficos
Autores principales:	Block, Geoffrey A, Pergola, Pablo E, Fishbane, Steven, Martins, Julian G, LeWinter, Robin D, Uhlig, Katrin, Neylan, John F, Chertow, Glenn M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603396/ https://www.ncbi.nlm.nih.gov/pubmed/30380116 http://dx.doi.org/10.1093/ndt/gfy318

Ejemplares similares

Hemoglobin response to ferric citrate in patients with nondialysis‐dependent chronic kidney disease and iron deficiency anemia
por: Pergola, Pablo E., et al.
Publicado: (2018)

Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease
por: Chertow, Glenn M., et al.
Publicado: (2017)

Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model
por: Brunelli, Steven M., et al.
Publicado: (2017)

Ferric Citrate Hydrate as a Phosphate Binder and Risk of Aluminum Toxicity
por: Gupta, Ajay
Publicado: (2014)

Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate
por: Yokoyama, Keitaro, et al.
Publicado: (2017)

Ferric citrate controls serum phosphorus in dialysis patients: retrospective data
por: Hain, Debra J., et al.
Publicado: (2017)

Antiviral effects of ferric ammonium citrate
por: Wang, Hongbin, et al.
Publicado: (2018)

Physicochemical characterization of ferric pyrophosphate citrate
por: Gupta, Ajay, et al.
Publicado: (2018)

Ferric pyrophosphate citrate: interactions with transferrin
por: Pratt, Raymond, et al.
Publicado: (2018)

The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia
por: Block, Geoffrey A, et al.
Publicado: (2019)

Safety and efficacy of ferric citrate in phosphate reduction and iron supplementation in patients with chronic kidney disease
por: Wu, Mei-Yi, et al.
Publicado: (2017)

Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients
por: Fishbane, Steven N., et al.
Publicado: (2015)

Segregating the effects of ferric citrate‐mediated iron utilization and FGF23 in a mouse model of CKD
por: Liesen, Michael P., et al.
Publicado: (2022)

Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study
por: Ito, Kyoko, et al.
Publicado: (2021)

Circulating Fibroblast Growth Factor-23 Levels are Associated with an Increased Risk of Anemia Development in Patients with Nondialysis Chronic Kidney Disease
por: Nam, Ki Heon, et al.
Publicado: (2018)

Mechanism of Action and Clinical Attributes of Auryxia(®) (Ferric Citrate)
por: Ganz, Tomas, et al.
Publicado: (2019)

Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis
por: Wolf, Myles, et al.
Publicado: (2019)

Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial
por: Roger, Simon D., et al.
Publicado: (2017)

A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial
por: Hanudel, Mark R., et al.
Publicado: (2022)

Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide
por: Nakayama, Masaaki, et al.
Publicado: (2017)

Individualized anemia management enhanced by ferric pyrophosphate citrate protocol
por: Chait, Yossi, et al.
Publicado: (2022)

Comparative Gut Microbiome Differences between Ferric Citrate and Calcium Carbonate Phosphate Binders in Patients with End-Stage Kidney Disease
por: Wu, Ping-Hsun, et al.
Publicado: (2020)

Reduction of costs for anemia-management drugs associated with the use of ferric citrate
por: Thomas, Anila, et al.
Publicado: (2014)

Ferric citrate is a safe and digestible source of iron in broilers and piglets
por: Männer, Klaus, et al.
Publicado: (2021)

Ferric Citrate Uptake Is a Virulence Factor in Uropathogenic Escherichia coli
por: Frick-Cheng, Arwen E., et al.
Publicado: (2022)

Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data
por: Rodby, Roger A., et al.
Publicado: (2015)

Comment on: “Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Mode”
por: Rascati, Karen
Publicado: (2017)

Resistant Hypertension in Nondialysis Chronic Kidney Disease
por: Borrelli, Silvio, et al.
Publicado: (2013)

Renoprotective effects of ferric citrate in a mouse model of chronic kidney disease
por: Hanudel, Mark R., et al.
Publicado: (2022)

Pharmacokinetics and Safety of Intravenous Ferric Pyrophosphate Citrate: Equivalence to Administration via Dialysate
por: Marbury, Thomas, et al.
Publicado: (2022)

Ferric citrate and ferric EDTA but not ferrous sulfate drive amphiregulin-mediated activation of the MAP kinase ERK in gut epithelial cancer cells
por: Scheers, Nathalie M., et al.
Publicado: (2018)

Ferric Citrate Hydrate Has Little Impact on Hyperplasia of Enterochromaffin Cells in the Rat Small Intestine Compared to Sodium Ferrous Citrate
por: Machida, Takuji, et al.
Publicado: (2022)

Phosphate and fibroblast growth factor 23 in diabetes
por: van der Vaart, Amarens, et al.
Publicado: (2021)

Linkage of Fibroblast Growth Factor 23 and Phosphate in Serum: Phosphate and Fibroblast Growth Factor 23 Reduction by Increasing Dose of Sevelamer
por: Ghorbanihaghjo, Amir, et al.
Publicado: (2018)

Conventional and novel impacts of ferric citrate on iron deficiency anemia and phosphorus metabolism in rats
por: IIDA, Akio, et al.
Publicado: (2020)

The fciTABC and feoABI systems contribute to ferric citrate acquisition in Stenotrophomonas maltophilia
por: Liao, Chun-Hsing, et al.
Publicado: (2022)

Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism
por: Saito, Tasuku, et al.
Publicado: (2009)

Ferric Phosphate Hydroxide Microstructures Affect Their Magnetic Properties
por: Zhao, Junhong, et al.
Publicado: (2015)

Pharmacokinetics of ferric pyrophosphate citrate administered via dialysate and intravenously to pediatric patients on chronic hemodialysis
por: Pratt, Raymond D., et al.
Publicado: (2018)

Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers
por: Pratt, Raymond D., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_crnka74mkbjnofj6k3ur5g813n